Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy.
Corine de JongGerarda J M HerderSimone W A van HaarlemFemke S van der MeerAnne S R van LindertAlexandra Ten HeuvelJan BrouwerAntoine C G EgbertsVera H M DeneerPublished in: Genes (2023)
Patients with the GG-genotype (rs879207) of TRPV1 have an almost 5-fold higher risk of developing severe neuropathy when treated with platinum-based therapy. Future studies should aim to validate these findings in an independent cohort and to further investigated the individualization of platinum-based chemotherapy in clinical practice.